Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 9,592 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 9,592 shares of Tempus AI stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $566,407.60. Following the sale, the chief executive officer directly owned 694,354 shares in the company, valued at approximately $41,001,603.70. This trade represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ryan Fukushima also recently made the following trade(s):

• On Monday, January 5th, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The shares were sold at an average price of $64.26, for a total transaction of $321,300.00.
• On Monday, December 1st, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The stock was sold at an average price of $75.72, for a total value of $378,600.00.

Tempus AI Trading Down 2.7%

TEM stock traded down $1.59 during midday trading on Friday, reaching $58.37. The company’s stock had a trading volume of 7,883,470 shares, compared to its average volume of 5,746,147. The business’s 50-day simple moving average is $62.60 and its 200-day simple moving average is $73.38. Tempus AI, Inc. has a 52 week low of $36.22 and a 52 week high of $104.32. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. The stock has a market cap of $10.38 billion, a PE ratio of -49.05 and a beta of 5.22.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently modified their holdings of TEM. Invesco Ltd. boosted its stake in Tempus AI by 21.5% during the fourth quarter. Invesco Ltd. now owns 371,674 shares of the company’s stock valued at $21,947,000 after buying an additional 65,836 shares during the period. Vident Advisory LLC lifted its stake in Tempus AI by 5.3% in the fourth quarter. Vident Advisory LLC now owns 10,376 shares of the company’s stock worth $613,000 after purchasing an additional 522 shares during the last quarter. Oracle Investment Management Inc. bought a new position in shares of Tempus AI during the fourth quarter valued at about $384,000. EP Wealth Advisors LLC bought a new position in shares of Tempus AI during the fourth quarter valued at about $553,000. Finally, Regal Partners Ltd purchased a new position in shares of Tempus AI in the fourth quarter worth about $531,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Analyst Ratings Changes

TEM has been the subject of several research analyst reports. Piper Sandler reduced their target price on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. JPMorgan Chase & Co. lowered their price objective on shares of Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Mizuho began coverage on shares of Tempus AI in a research note on Thursday. They issued an “outperform” rating and a $100.00 price objective on the stock. Finally, Robert W. Baird started coverage on Tempus AI in a report on Tuesday. They issued an “outperform” rating and a $59.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $85.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.